Neuronal PPP2R5C in plasma is a potential biomarker for early diagnosis of Alzheimer's disease

血浆中的神经元 PPP2R5C 是一种潜在的阿尔茨海默病早期诊断生物标志物

阅读:1

Abstract

BACKGROUND: Overwhelming studies have demonstrated that implementing an early intervention is the most effective strategy to impede the advancement of Alzheimer's disease (AD), depending on the identification of early diagnostic biomarkers. METHOD: In this study, we first employed proteomics to identify differentially expressed proteins in neuron‐derived exosomes (NDEs) from plasma samples of 13 familial AD (FAD) patients, 10 pre‐FAD patients, and 18 cognitively normal (CN) controls. These findings were subsequently validated using targeted mass spectrometry in a cohort of sporadic AD individuals. Enzyme‐linked immunosorbent assay (ELISA) was utilized for further validation in a larger cohort comprising 74 AD patients, 76 individuals with amnestic mild cognitive impairment (aMCI), and 74 healthy controls. Additionally, the diagnostic performance of PPP2R5C was evaluated by analyzing 34 AD patients, 28 progressive supranuclear palsy (PSP) patients, and 37 frontotemporal dementia (FTD) patients. Meanwhile, the mechanism underlying PPP2R5C's role in AD pathogenesis was explored through in vitro and in vivo models. RESULT: Our findings reveal a trend of decreased PPP2R5C protein levels in NDEs across FAD, pre‐FAD, and CN (FAD < pre‐FAD < CN), as well as a similar downward trend in plasma PPP2R5C levels within the AD cohort (AD < aMCI < CN, p <0.05). Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Plasma PPP2R5C demonstrated significant diagnostic ability for AD (AUC = 0.84, p < 0.0001) and for aMCI (AUC = 0.74, p < 0.0001). Mechanistically, we found that PPP2R5C interacts with Tau and attenuates both its total and phosphorylated levels, either by mediating the autophagolysosomal pathway or directly influencing PP2A activity. Furthermore, PPP2R5C‐mediated autophagy was shown to be dependent on its binding activity to unc‐51‐like kinase 1 (ULK1). CONCLUSION: This study suggested that plasma PPP2R5C could be a novel and ideal biomarker for the early diagnosis of AD and its involvement in the pathogenesis of AD

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。